Featured Press Releases

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog®

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog®

UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP

UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP

  • 29 Mar 2024

Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the recent launch of Methimazole Tablets,...

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

Leqembi® approved in Mexico

Leqembi® approved in Mexico

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

CorrectSequence Therapeutics

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

  • Asahi Kasei
  • 13 Nov 2025
Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

  • Odyssey Therapeutics, Inc.
  • 11 Nov 2025
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

  • HanchorBio Inc.
  • 10 Nov 2025
VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

  • Organon & Co.
  • 10 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.